@import url(http://finance.paidcontent.org/client/paidcontent/privatelabel.css);
February 24, 2012 at 10:26 AM EST
Access Pharma Gains SFDA Approval for Oral Mucositis Treatment
Access Pharmaceuticals announced that MuGard™, its treatment for oral mucositis in cancer patients, received SFDA marketing approval. RHEI Pharmaceuticals HK Ltd. handled the regulatory process for Access, and Jian An Pharma will market the product in China and Taiwan. Access out-licensed China rights for MuGard to RHEI Pharma in 2008. More details.... Stock Symbol: (OTCBB: ACCP) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here